Teduglutide
GLP-2 receptor agonist approved as Gattex for short bowel syndrome. Promotes intestinal growth, nutrient absorption, and gut barrier function; distinct receptor from GLP-1 agents.
0 anonymous reports
Also known as:
gattexrevestiveglp-2 analogue
browse topics:
No reports found.
Community Q&A
- What is the difference between GLP-2 and GLP-1?
- Community accounts consistently distinguish the two: GLP-1 acts on appetite and insulin signalling (the basis of Ozempic-type compounds); GLP-2 acts specifically on intestinal epithelium — stimulating gut wall growth, improving nutrient absorption, and strengthening the gut barrier. Teduglutide is described in accounts as a gut-specific healing compound rather than an appetite or metabolic agent. The two pathways are described as complementary rather than overlapping.
- Who uses teduglutide in the community?
- Community accounts describing teduglutide use come almost exclusively from two groups: short bowel syndrome patients where it is the standard of care, and users with severe inflammatory bowel conditions exploring intestinal regeneration. Off-label use in the broader gut healing community is rare compared to BPC-157 or KPV — teduglutide's prescription requirement and cost are cited as the primary barriers. Accounts that have used it describe dramatic intestinal improvements beyond what other gut healing peptides produced.